Mankind Pharma Limited (BOM:543904)
India · Delayed Price · Currency is INR | Market Cap | 1.02T -4.0% |
| Revenue (ttm) | 147.38B +14.2% |
| Net Income | 20.43B +7.9% |
| EPS | 49.42 +6.5% |
| Shares Out | n/a |
| PE Ratio | 49.93 |
| Forward PE | 40.66 |
| Dividend | 1.00 (0.04%) |
| Ex-Dividend Date | Aug 8, 2025 |
| Volume | 111,909 |
| Open | 2,600.10 |
| Previous Close | 2,576.95 |
| Day's Range | 2,422.00 - 2,613.75 |
| 52-Week Range | 1,909.90 - 2,670.00 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 2,736.47 (+10.03%) |
| Earnings Date | Jul 30, 2026 |
About Mankind Pharma
Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, gynaecology, urology, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, respiratory, and other diseases. It also provides consumer healthcare products, such as condoms, pregnancy detection, emergency contraceptives, antacid pow... [Read more]
Financial Performance
In fiscal year 2026, Mankind Pharma's revenue was 142.78 billion, an increase of 16.96% compared to the previous year's 122.07 billion. Earnings were 19.13 billion, a decrease of -3.92%.
Financial StatementsAnalyst Summary
According to 19 analysts, the average rating for 543904 stock is "Buy." The 12-month stock price target is ₹2,736, which is an increase of 10.03% from the latest price.
News
Mankind Pharma Transcript: Q1 26/27
Q1 FY 2027 delivered 13% revenue growth and 29% PAT growth year-over-year, with strong chronic and BSV specialty performance, improved margins, and robust international expansion. Guidance remains for double-digit growth, high margins, and continued debt reduction.
Mankind Pharma Quarterly report: Q1 2027
Mankind Pharma has published its Q1 2027 quarterly earnings report on July 30, 2026.
Mankind Pharma Slides: Q1 2027
Mankind Pharma has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on July 30, 2026.
Mankind Pharma Transcript: Q4 25/26
Q4 and FY26 saw strong revenue and margin growth, led by domestic and specialty businesses, with chronic therapies outperforming and OTC channels expanding. FY27 guidance targets double-digit revenue growth, higher CapEx for biotech, and improved margins, despite raw material cost risks.
Mankind Pharma Quarterly report: Q4 2026
Mankind Pharma has published its Q4 2026 quarterly earnings report on May 20, 2026.
Mankind Pharma Slides: Q4 2026
Mankind Pharma has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 20, 2026.
Mankind Pharma Annual report: Q4 2026
Mankind Pharma has published its Q4 2026 annual report on May 20, 2026.
Mankind Pharma Transcript: Q3 25/26
Revenue and profit grew year-over-year, driven by strong chronic therapy and export performance, while acute and OTC segments are recovering post-restructuring. Working capital and debt metrics improved, and management expects double-digit growth ahead.
Mankind Pharma Quarterly report: Q3 2026
Mankind Pharma has published its Q3 2026 quarterly earnings report on February 3, 2026.
Mankind Pharma Slides: Q3 2026
Mankind Pharma has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on February 3, 2026.
Mankind Pharma Transcript: Q2 25/26
Revenue grew 21% year-on-year in Q2 FY26, with EBITDA margin at 25%, but profit after tax declined 21% due to higher costs from BSV consolidation. Domestic and export businesses showed strong growth, while GST disruptions and restructuring impacted margins. Guidance for FY26 EBITDA margin and BSV growth is maintained.
Mankind Pharma Quarterly report: Q2 2026
Mankind Pharma has published its Q2 2026 quarterly earnings report on November 6, 2025.
Mankind Pharma Slides: Q2 2026
Mankind Pharma has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on November 6, 2025.